Physician profile
Natalie C Eberle
NPI 1497428247
$2,231.51
in general payments reported to CMS, 2019-2025
21 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $352 · 2022: $525 · 2023: $527 · 2024: $639 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.03 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $546.78 | 2024-2025 | |
| Boston Scientific Corporation | $235.75 | 2022-2023 | Watchman Access System |
| Sobi, INC | $235.66 | 2024 | |
| Abbvie INC. | $234.74 | 2021-2023 | |
| Novo Nordisk INC | $183.90 | 2021-2023 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $134.90 | 2023 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $119.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $113.34 | 2021 | |
| Glaxosmithkline, LLC. | $112.89 | 2022 | |
| Janssen Scientific Affairs, LLC | $44.57 | 2022 | |
| Edwards Lifesciences Corporation | $42.65 | 2023 | |
| Merck Sharp & Dohme LLC | $41.93 | 2022-2023 | Verquvo |
| Kite Pharma, INC. | $28.57 | 2024 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $26.94 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.45 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $24.38 | 2022 | |
| Impulse Dynamics (USA) INC. | $20.09 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.32 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $17.42 | 2025 | |
| Amgen INC. | $13.09 | 2023 | Repatha |
| Pfizer INC. | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Eberle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.